



## **AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference**

February 17, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 17, 2021-- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021 at 4:20 p.m. ET.

The presentation will be available on the Investors & Press section of the AlloVir website at <https://ir.allovir.com>. An archived replay of the presentation will be available for approximately 30 days following the presentation.

### **About AlloVir**

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single and multi-virus specific T-cells targeting devastating viruses for patients with T-cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit [www.allovir.com](http://www.allovir.com).

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20210217005078/en/>

### **Media contact:**

Courtney Heath  
ScientPR

[AlloVirPR@scientpr.com](mailto:AlloVirPR@scientpr.com)

617-872-2462

### **Investor contact:**

Medha Chadha  
AlloVir

[ir@allovir.com](mailto:ir@allovir.com)

Source: AlloVir, Inc.